BLLNHealthcare · Diagnostics & ResearchThe 8 Wall Street analysts covering BillionToOne, Inc. hold a median 12-month price target of $130 — +14.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores BillionToOne, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (63): Analysts have, on balance, been raising their forecasts.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BLLN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.1% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $125 → $128 |
| 2 Sept 2026 | Canaccord Genuity | Initiates | Buy | — |
| 2 Sept 2026 | Canaccord Genuity | Initiates | Buy | $120 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | $142 → $130 |
| 6 Aug 2026 | JP Morgan | Maintains | Overweight | $145 → $130 |
| 6 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 29 June 2026 | Guggenheim | Initiates | Buy | — |
| 29 June 2026 | Guggenheim | Initiates | Buy | $120 → $125 |
| 13 May 2026 | Guggenheim | Maintains | Buy | — |
| 7 May 2026 | BTIG | Maintains | Buy | — |
| 7 May 2026 | JP Morgan | Maintains | Overweight | — |
| 30 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 5 Mar 2026 | BTIG | Maintains | Buy | — |
| 5 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 5 Mar 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 10 Dec 2025 | BTIG | Reiterates | Buy | — |
| 10 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 1 Dec 2025 | BTIG | Initiates | Buy | — |
| 1 Dec 2025 | Jefferies | Initiates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BLLN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 4% of US stocks
Cheaper than 11% of US stocks
Cheaper than 9% of US stocks
Cheaper than 2% of US stocks
Higher than 89% of US stocks
Higher than 78% of US stocks
Higher than 83% of US stocks
Higher than 55% of US stocks
Higher than 66% of US stocks
Higher than 65% of US stocks
Higher than 78% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BillionToOne, Inc. has a market value of $5.4B and an enterprise value of $5.0B.
Revenue in the twelve months to 30 June 2026: $397.4M. The latest quarter grew 64.4% year on year.
Net income over the same four quarters: $37.7M, a 9.5% net margin.
Diluted earnings per share, trailing twelve months: $0.73.
Free cash flow in the twelve months to 30 June 2026: $33.1M.
Trailing P/E: 180.8×; forward P/E: 76.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BillionToOne, Inc. employs 713 people — $557K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BillionToOne, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of BillionToOne, Inc.’s Q3 2026 earnings call.
Why it matters — The transcript provides BLLN watchers with the company’s discussion during its Q3 2026 earnings call.
Zacks Investment Research notes that BillionToOne reported Q3 earnings for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago values. The excerpt provides no specific results or comparisons.
Why it matters — BLLN watchers may use these metric comparisons to assess the quarterly performance, but the excerpt does not state their outcomes.
BillionToOne reported quarterly earnings of $0.32 per share, above the Zacks Consensus Estimate of $0.16. This compares with earnings of $0.10 per share a year earlier.
Why it matters — The per-share earnings exceeded the consensus estimate, providing BLLN watchers an update on quarterly results versus expectations.
BillionToOne raised its full-year revenue outlook after third-quarter sales increased 47% year over year, with growth in prenatal and oncology testing. It also reported its fifth consecutive quarter of positive GAAP operating income.
Why it matters — The outlook increase, sales growth and continued positive GAAP operating income are relevant updates for BLLN watchers.
BillionToOne reported financial results for the third quarter ended September 30, 2026, and raised its full-year 2026 revenue guidance.
Why it matters — The results and higher revenue guidance are updates on the company’s financial performance and outlook for 2026.
The 8 Wall Street analysts covering BillionToOne, Inc. have a median 12-month price target of $130, with estimates ranging from $110 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering BillionToOne, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BillionToOne, Inc. 18 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, BillionToOne, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +14.1% from the last close, and Ticker Nerd's factor model ranks BillionToOne, Inc. 18 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BillionToOne, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $145 over the next 12 months.
BillionToOne Inc. Class A Common Stock represents equity in BillionToOne, a molecular diagnostics company focused on precision testing for clinical use.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of BillionToOne, Inc.’s Q3 2026 earnings call.
BillionToOne Inc. Class A Common Stock represents equity in BillionToOne, a molecular diagnostics company focused on precision testing for clinical use. The company develops advanced DNA-counting technology designed to detect and measure genetic material with high sensitivity, supporting applications in prenatal screening, cancer testing, and other diagnostic workflows. Its product portfolio includes non-invasive prenatal tests, liquid biopsy solutions, and response-monitoring assays used by healthcare providers and laboratories to assess genetic risk and disease status from blood-based samples. BillionToOne serves the broader healthcare diagnostics market, where accurate, minimally invasive testing plays an important role in improving clinical decision-making and expanding access to molecular diagnostics. The company is headquartered in Menlo Park, California.
CEO Dr. Oguzhan Atay Ph.D. · 713 employees · United States · https://www.billiontoone.com
